The FDA Reboot of Antibiotic Development

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments

(2013) John H Rex et al.   LANCET INFECTIOUS DISEASES

The Future of Antibiotics and Resistance

(2013) Brad Spellberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

White Paper: Recommendations on the Conduct of Superiority and Organism-Specific Clinical Trials of Antibacterial Agents for the Treatment of Infections Caused by Drug-Resistant Bacterial Pathogens

(2012)   CLINICAL INFECTIOUS DISEASES

A long and winding road; evolution of antimicrobial drug development – crisis management

(2012) Roger M Echols   Expert Review of Anti-Infective Therapy

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure

(2012) Brad Spellberg et al.   NATURE REVIEWS DRUG DISCOVERY

Acute Bacterial Skin and Skin Structure Infection Trials: The Bad is the Enemy of the Good

(2011) B. Spellberg   CLINICAL INFECTIOUS DISEASES

Fix the antibiotics pipeline

(2011) Matthew A. Cooper et al.   NATURE

Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007

(2008) Alicia I. Hidron et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Telithromycin and the FDA: implications for the future

(2008) David M Shlaes et al.   LANCET INFECTIOUS DISEASES